A novel approach to assess the spontaneous gastrointestinal bleeding risk of antithrombotic agents using Apcmin/+ mice

Thrombosis and Haemostasis

Volumn 111, Issue 6, 2014, Pages 1121-1132

  Wei, Huijun ^a   Shang, Jin ^a   Keohane, CarolAnn ^a   Wang, Min ^a   Li, Qiu ^a   Ni, Weihua ^a   O'Neill, Kim ^a   Chintala, Madhu ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antithrombotic; Bleeding; Gastrointestinal; Spontaneous

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A; CHOLESTEROL; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; FIBRINOGEN; HEMOGLOBIN; THROMBIN; TRIACYLGLYCEROL; WARFARIN; BENZIMIDAZOLE DERIVATIVE; FIBRINOLYTIC AGENT; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; TICLOPIDINE;

ACTIVATED PARTIAL THROMBIN TIME; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; DISEASE SEVERITY; GASTROINTESTINAL HEMORRHAGE; HEMATOCRIT; HYPERCOAGULABILITY; MALE; MOUSE; NONHUMAN; OCCULT BLOOD; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK; THROMBIN TIME; THROMBOCYTE AGGREGATION INHIBITION; AGE; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG SCREENING; GENETICS; MUTANT MOUSE STRAIN; RISK FACTOR; TUMOR SUPPRESSOR GENE;

AGE FACTORS; ANIMALS; BENZIMIDAZOLES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FIBRINOLYTIC AGENTS; GASTROINTESTINAL HEMORRHAGE; GENES, APC; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PYRAZOLES; PYRIDINES; PYRIDONES; RISK FACTORS; TICLOPIDINE; WARFARIN;

EID: 84901952043     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-11-0926     Document Type: Article

References (23)

1. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009; 361: 1139-1151.
3. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012; 108: 476-484.
4. Holster IL, Valkhoff VE, Kuipers EJ, et al. New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding-A Systematic Review and Meta-Analysis. Gastroenterology 2013; Epub ahead of print.
5. Morowski M, Vogtle T, Kraft P, et al. Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice. Blood 2013; 121: 4938-4947.
6. Littlewood JD, Bevan SA, Kemball-Cook G, et al. In vivo studies of activated porcine factor VIII. Thromb Haemost 1996; 76: 743-748.
7. Weitz JI. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding. J Vasc Interv Radiol 1995; 6 (6 Pt 2 Suppl): 19S-23S.
8. Hong TT, Huang J, Driscoll E, et al. The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study). J Cardiovasc Pharmacol 2005; 46: 526-533.
9. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991; 77: 2547-2552.
10. Lind SE. Prolonged bleeding time. Am J Med 1984; 77: 305-312.
11. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Seminars Thromb Haemost 1990; 16: 1-20.
12. Horisawa S, Kaneko M, Sakurama T. SM-20302, a nonpeptide GPIIb/IIIa receptor antagonist, exhibits a wide therapeutic window in a newly developed haemorrhage model in mice. Thromb Haemost 1999; 82: 1743-1748.
13. Melarange R, Moore G, Blower PR, et al. A comparison of indomethacin with ibuprofen on gastrointestinal mucosal integrity in conventional and germ-free rats. Alimentary Pharmacol Therap 1992; 6: 67-77.
14. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990; 247: 322-324.
15. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science 1997; 275: 1784-1787.
16. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790.
17. Chintala M, Strony J, Yang B, et al. SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscl Thromb Vasc Biol 2010; 30: 2143-2149.
18. Niho N, Takahashi M, Kitamura T, et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003; 63: 6090-6095.
19. Sun S, Wang M, Su L, et al. Study on warfarin plasma concentration and its correlation with international normalized ratio. J Pharm Biomed Analysis 2006; 42: 218-222.
20. Clemens A, Haertter S, Friedman J, et al. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin 2012; 28: 195-201.
21. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
22. Harlow P. pharmacology review(s) of Drug Approval Package, Eliquis, application No: 202155. FDA; 2012; 138.
23. Leil TA, Feng Y, Zhang L, et al. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Therap 2010; 88: 375-382.